APA

Seki N., Brooks A. D., Carter C. R. D., Back T. C., Parsoneault E. M., Smyth M. J., Wiltrout R. H. & Sayers T. J. (20020508). Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. : Journal of immunology (Baltimore, Md. : 1950).

Chicago

Seki Naoko, Brooks Alan D, Carter Clive R D, Back Timothy C, Parsoneault Erin M, Smyth Mark J, Wiltrout Robert H and Sayers Thomas J. 20020508. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. : Journal of immunology (Baltimore, Md. : 1950).

Harvard

Seki N., Brooks A. D., Carter C. R. D., Back T. C., Parsoneault E. M., Smyth M. J., Wiltrout R. H. and Sayers T. J. (20020508). Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. : Journal of immunology (Baltimore, Md. : 1950).

MLA

Seki Naoko, Brooks Alan D, Carter Clive R D, Back Timothy C, Parsoneault Erin M, Smyth Mark J, Wiltrout Robert H and Sayers Thomas J. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. : Journal of immunology (Baltimore, Md. : 1950). 20020508.